5 Best Peptides for Sexual Performance

What to Know Before Choosing a Peptide for Sexual Performance

Sexual performance is not a single problem with a single solution. It spans desire, arousal, hormonal balance, blood flow, emotional connection, and nerve signaling, and different peptides address different parts of that picture. The compounds on this list were included because people genuinely use them or are actively discussing using them for this goal. That is the whole test. FDA approval, published trial data, and commercial availability are all relevant to how each compound is described, but none of them are the filter for whether a compound appears here.

That means this list includes an FDA-approved option, an investigational compound with Phase I and II clinical trial data, a peptide whose evidence is largely community-reported, and everything in between. Where the evidence is strong, it is described as strong. Where no human clinical trial exists, that is stated plainly inside the entry. Evidence strength shapes how a compound is described, never whether it shows up.

The entries are numbered by how prominently each compound appears in research and documented real-world use for sexual performance, not as a recommendation of one compound over another. A lower number reflects a deeper and broader presence in both the published literature and practical community use. The right compound for any individual depends on what is actually driving their situation, and that personalized decision belongs in the MyPeptidePal app, not in a list.

1. PT-141 (Bremelanotide): On-Demand Arousal and Desire

PT-141, sold under the brand name Vyleesi, is the only FDA-approved peptide for a sexual performance indication. It received that approval in 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women, meaning clinically low sexual desire that causes personal distress. Beyond that approved population, it has become the most widely used and most frequently discussed peptide for sexual performance across both sexes, making it the natural anchor of any honest list on this topic.

What sets PT-141 apart from the PDE5 inhibitors most people are familiar with, drugs like sildenafil and tadalafil, is where it acts. PDE5 inhibitors work on peripheral blood vessels to improve blood flow to genital tissue. PT-141 works upstream of that, in the brain itself. It activates melanocortin receptors called MC4R and MC3R in the hypothalamus, a part of the brain that governs fundamental drives including sexual motivation. That receptor activation triggers a cascade that releases dopamine in the brain's mesolimbic reward system (the circuit governing desire and wanting) and activates the neurons that release oxytocin. The result is sexual desire and arousal that originates centrally rather than peripherally, which is why PT-141 can produce a response even in people whose vascular health makes PDE5 inhibitors ineffective. It addresses the neurological origin of arousal, not just the downstream mechanical endpoint.

The clinical evidence for PT-141 in women is the strongest of any peptide in this space. The Phase 3 RECONNECT trials enrolled over 1,200 premenopausal women with HSDD and found statistically significant increases in sexual desire alongside meaningful reductions in desire-related distress. That data formed the basis of FDA approval. For men, the picture is smaller but real: a small intranasal trial found a 33.5 percent positive response compared to 8.5 percent on placebo, and a later subcutaneous dose trial reported improved sexual function in over half of participants. No large-scale Phase 3 randomized controlled trial exists specifically for male erectile dysfunction yet, so male use remains off-label and is supported by smaller trials alongside extensive community data.

Real-world experience with PT-141 is the most extensive of any compound on this list. Across community discussion, it is the most frequently cited peptide for sexual performance by a significant margin. Users consistently report rapid onset of arousal and, for men, improved erection quality. Nausea is the most commonly reported side effect and occurs in roughly 40 percent of users in clinical data, with severity increasing at higher doses. Flushing, headache, and a transient increase in blood pressure are also reported. A consistent minority of users report no response or even decreased desire, which reflects genuine individual variability in how this compound works. PT-141 is available by prescription under the Vyleesi brand for women with HSDD and through compounding pharmacies via telehealth and functional medicine clinics for off-label use, though compounded formulations do not carry FDA approval.

2. Kisspeptin-10: Hormonal Optimization for Low Drive

Kisspeptin-10, also referred to as KP-10, is an endogenous neuropeptide produced naturally by the body's KISS1 gene. It occupies a position at the very top of the hormonal axis that governs testosterone production, and that is what makes it relevant to sexual performance in a way that is fundamentally different from PT-141. Where PT-141 generates on-demand arousal through direct CNS signaling, Kisspeptin-10 works through the body's own hormonal architecture to address the underlying insufficiency that can gradually erode sexual drive.

The mechanism runs through what researchers call the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin binds to KISS1R receptors on neurons that release gonadotropin-releasing hormone (GnRH), essentially the master switch for sex hormone production. GnRH signals the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then travels to the testes and signals Leydig cells to produce testosterone. Kisspeptin also appears to act directly on sexual brain regions to influence desire independent of testosterone, and it initiates nitric oxide release as a parallel signal connected to arousal. The practical implication of all this is that Kisspeptin-10 is a long-term hormonal support tool rather than an on-demand performance compound. Someone whose low libido traces to hypogonadism or hormonal decline is a more natural candidate for it than someone seeking acute arousal enhancement.

The clinical evidence is at Phase I and II level, which is earlier than PT-141's Phase 3 foundation but more substantial than most peptides at this stage. Randomized trials in men found increases in penile tumescence of up to 56 percent compared to placebo. A study published in JAMA Network Open confirmed that kisspeptin improves sexual brain processing and desire-related behavior in both men and women with HSDD, and did so independently of testosterone levels, which suggests its central arousal effects are not purely mediated by the hormonal pathway. Research from Imperial College London has specifically examined kisspeptin injections as a potential treatment for low libido. None of this has reached FDA approval yet, and realistic clinical availability is projected several years out, but the investigational evidence base is genuinely encouraging.

Community reports for Kisspeptin-10 are less extensive than PT-141, which reflects its more limited availability as a research compound. Users who have accessed it describe a qualitatively different experience from PT-141: not a rapid on-demand arousal effect but something closer to a gradual hormonal restoration, with improved libido and mood developing over time. It is most relevant for people whose reduced sexual drive has a clear hormonal component.

3. Melanotan-2: Tanning Compound with Arousal Effects

Melanotan-2 (MT-II) sits in an unusual position on this list. It was not designed as a sexual performance compound, and most people who use it are not primarily seeking that effect. Its marketed purpose is skin tanning. The libido and arousal effects are physiological side effects that became well known enough in community and clinical circles that some people seek it out specifically for them. Understanding that origin is essential to understanding both what it can do and why it carries a higher-risk profile than the compounds above it.

Melanotan-2 is a non-selective melanocortin agonist, which means it activates a broader range of melanocortin receptors than PT-141 does. PT-141 was actually derived from Melanotan-2 and deliberately engineered to be more selective, retaining the MC4R and MC3R activity that produces arousal while eliminating the MC1R activation that causes skin darkening. Melanotan-2 activates all four receptor subtypes. MC1R activation produces the tanning effect. MC4R activation produces the sexual arousal response. That broader receptor coverage is precisely why Melanotan-2 carries a heavier side-effect burden and why PT-141 has largely replaced it for people whose primary interest is sexual performance.

Placebo-controlled trials in men with psychogenic erectile dysfunction found that Melanotan-2 induced erections in most participants and increased both sexual desire and penile rigidity. That evidence base exists. It also comes with a significant clinical caveat: widespread use for sexual performance has been described in clinical commentary as scientifically unjustified given the compound's safety profile and the absence of an active regulatory pathway for this indication. The specific safety concerns that distinguish it from PT-141 include a meaningful risk of priapism (spontaneous erections without stimulation), darkening of existing moles, and a potential melanoma risk with prolonged use. These are not theoretical concerns but findings from clinical and community observation.

Community reports are mixed. Some users describe meaningful libido enhancement, particularly those who sought the dual benefit of tanning and arousal in one compound. Others report no libido effect and describe preferring PT-141 when sexual performance is the sole goal. The community consensus is fairly consistent on this: PT-141 is the preferred option for sexual performance specifically, and Melanotan-2 is the choice when tanning and libido together are the objective. The mole-darkening and priapism risks mean this compound warrants physician involvement and careful consideration before use, particularly given that available formulations outside of clinical settings lack regulatory oversight.

4. Oxytocin: Emotional Connection and Sensory Enhancement

Oxytocin is a nine-amino-acid peptide produced naturally by the hypothalamus and released by the pituitary gland. It is probably the most recognized peptide in the popular science conversation under the name "the bonding hormone" or "the love hormone," and those labels, while reductive, capture something real about its role in sexual performance. Oxytocin does not drive libido in the way PT-141 does and does not address hormonal insufficiency the way Kisspeptin-10 does. What it addresses is the emotional and relational dimension of sexual performance, specifically the quality of connection, arousal sensitivity, and orgasm intensity.

The mechanism involves oxytocin receptors distributed across the brain and peripheral tissues. Activation of these receptors enhances the neurological processing of social bonding, increases emotional attunement between partners, and heightens physical sensitivity during intimacy. Orgasm intensity is meaningfully connected to oxytocin signaling: the compound is released in surges during orgasm, and supplementing with it can amplify that response. There is also a mechanistic link between oxytocin and PT-141 worth noting. PT-141's activation of melanocortin receptors in the hypothalamus triggers oxytocinergic neurons as part of its arousal cascade. The two compounds share overlapping downstream effects, which is why some users combine them to address both the desire component and the emotional or sensory component together.

Oxytocin has FDA approval for obstetric uses, specifically labor induction, which reflects its well-established safety profile as an endogenous compound. It does not have approval for sexual performance enhancement. The clinical evidence most directly relevant to sexual performance comes from research on bonding, emotional responsiveness, and arousal sensitivity rather than from trials specifically designed around desire disorders or erectile function. The evidence base here is more mechanistic and observational than the controlled trial data available for PT-141 or Kisspeptin-10. No large-scale randomized controlled trial has established oxytocin's efficacy specifically for HSDD or erectile dysfunction.

Real-world use centers on couples seeking a deeper emotional quality to intimacy alongside whatever else they may be using. Oxytocin's primary route for sexual performance use is intranasal spray, making it the most accessible delivery format on this list. Users taking it intranasally before intimacy report heightened feelings of connection and improved physical sensitivity. It is used both as a standalone compound and in combination with PT-141, particularly by people who find PT-141 handles the arousal component but want to reinforce the emotional dimension. The evidence here is experiential rather than clinical for the sexual performance application specifically, which does not diminish its real-world prevalence but is worth stating plainly.

5. BPC-157: Nerve-Based Dysfunction and Post-SSRI Recovery

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide derived from a protein found naturally in gastric juice. It is most widely known for tissue repair, tendon healing, and gut health, and it does not directly improve blood flow to genital tissue or drive libido in the way the compounds above it do. Its place on a sexual performance list reflects a specific and growing body of community use for a particular category of sexual dysfunction: Post-SSRI Sexual Dysfunction (PSSD) and other cases involving reduced genital sensation, diminished orgasm quality, or nerve-related disruption to sexual response.

The mechanistic reasoning is grounded in BPC-157's neuro-repair properties. Studies in animal models have examined its effects on nerve regeneration, reduction of neuroinflammation, and restoration of signaling in damaged tissue. The community hypothesis applied to sexual dysfunction is that these same properties can address the sensory and orgasmic components of sexual function that are disrupted by SSRI use or other nerve-affecting factors. To be clear about what BPC-157 is not doing in this context: it is not a blood-flow compound. It does not address the mechanics of erection or penile engorgement. Its reported value is specific to sensation and orgasm quality, not to vascular erectile function.

No published human clinical trial data exists for BPC-157 in sexual dysfunction as of 2026. The basis for its inclusion here is community-reported use, which is substantial enough and specific enough to take seriously. Across discussion in PSSD-focused communities, users report restoration of genital sensation and improved orgasm intensity following BPC-157 use, with effects appearing on timelines ranging from one day to ten days of use. What gives these reports more weight than generic positive anecdotes is their internal consistency: the community accounts are coherent about both what BPC-157 helps (sensation, orgasm quality) and what it does not help (blood-flow-based erectile insufficiency). That specificity suggests a real signal rather than placebo-driven enthusiasm.

BPC-157 is not FDA-approved for any indication as of 2026 and is available as a research compound through some compounding pharmacies. Its safety profile in published research for tissue repair applications is generally favorable in animal models, but the long-term safety picture for extended use specifically in sexual dysfunction has not been examined clinically. Anyone considering it for PSSD or related sensory dysfunction should discuss this with a physician who has familiarity with the underlying condition.

How These Peptides Compare

Frequently Asked Questions

Is PT-141 available for men as well as women?

PT-141 is FDA-approved specifically for premenopausal women with hypoactive sexual desire disorder, and that approved indication does not extend to men. Men use it off-label through compounding pharmacies and telehealth clinics operating under physician supervision, and smaller clinical trials have demonstrated measurable positive responses in male populations. The off-label status means it is not covered by the formal approval but is used in clinical practice under physician guidance.

How is using a sexual performance peptide different from taking Viagra or Cialis?

PDE5 inhibitors like sildenafil and tadalafil act on peripheral blood vessels to increase blood flow to genital tissue, addressing the mechanical side of erectile function without affecting desire. Most sexual performance peptides, and PT-141 most clearly, act in the brain to generate desire and arousal centrally. That central mechanism is why PT-141 can be effective in people who do not respond to PDE5 inhibitors due to vascular issues, and it is also why some people use both approaches together under physician supervision when the problem involves both desire and vascular function.

How long do these compounds take to produce an effect?

Timing varies considerably by compound and by what mechanism is involved. PT-141 is typically used 30 to 45 minutes before sexual activity, with onset reported in that window. Oxytocin administered intranasally is typically taken 15 to 30 minutes beforehand. Kisspeptin-10 works through the hormonal axis, so changes in testosterone and libido develop gradually over ongoing use rather than acutely. BPC-157, when used for nerve-related sensory dysfunction, is described in community accounts as producing effects over one to ten days of use rather than as a single-dose response.

Are there specific concerns about sourcing and product quality with these compounds?

Yes, and this is one of the most practically important safety considerations. For PT-141, the FDA-approved Vyleesi formulation is subject to manufacturing and quality oversight. Compounded versions and research-chemical formulations available through other channels are not held to those same standards, and purity, potency, and accurate labeling cannot be guaranteed. Melanotan-2 in particular circulates widely through unregulated channels where quality is especially variable. For any compound on this list, physician involvement and sourcing through verifiable channels are meaningful risk-reduction steps, not optional extras.

Do any of these peptides work specifically for hormonal causes of low libido?

Kisspeptin-10 is the most directly targeted compound for hormonally driven low libido. Its mechanism works through the HPG axis to stimulate the body's own testosterone production, which makes it particularly relevant for hypogonadism and age-related hormonal decline. Phase I and II clinical trial data specifically confirms improvements in desire-related measures in people with HSDD independent of testosterone levels, which suggests central arousal effects beyond the hormonal pathway as well. It is investigational as of 2026, but the evidence base is stronger than most peptides at this stage of development.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for sexual performance in one place.